Abstract
The recent Food and Drug Administration and European Medicine Agency regulatory approval of intranasal (S)-Ketamine for the treatment-resistant depression in adults and its quick introduction in everyday psychiatric practice might be considered as a second revolution in the field of neuropsychopharmacology after the first one, which started over 50 years ago with the discovery of the monoaminergic antidepressants. This chapter will present the critical antidepressant features of Ketamine, including its putative mechanisms of action and other Ketamine-like glutamatergic drugs in development for the treatment of chronic stress-related psychiatric disorders. First, a detailed picture of NMDA-dependent and independent glutamatergic mechanisms mediating Ketamine effects will be given. The following section will be dedicated to an in-depth description of cellular and molecular mechanisms which have been suggested to underlie the fast antidepressant properties of Ketamine. Alternative investigational therapeutic uses of Ketamine (besides as an antidepressant) will then be presented, followed by the description of other glutamatergic drugs which received significant attention for their potential antidepressant effects.
The following part will be dedicated to limitations related to Ketamine use. Finally, we will share our insights and provide recommendations on the future perspectives in the prevention and early management of chronic stress and stress-related disorders, focusing on glutamate-based aspects of proposed interventions.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abdallah CG, Salas R, Jackowski A et al (2015a) HIPPampal volume and the rapid antidepressant effect of Ketamine. J Psychopharmacol 29:591–595. https://doi.org/10.1177/0269881114544776
Abdallah CG, Sanacora G, Duman RS, Krystal JH (2015b) Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu Rev Med 66:509–523. https://doi.org/10.1146/annurev-med-053013-062946
Abdallah CG, Jackowski A, Salas R et al (2017) The nucleus accumbens and ketamine treatment in major depressive disorder. Neuropsychopharmacology 42:1739–1746. https://doi.org/10.1038/npp.2017.49
Abdallah CG, De Feyter HM, Averill LA et al (2018a) The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. Neuropsychopharmacology 43:2154–2160. https://doi.org/10.1038/s41386-018-0136-3
Abdallah CG, Dutta A, Averill CL et al (2018b) Ketamine, but not the NMDAR antagonist lanicemine, increases prefrontal global connectivity in depressed patients. Chronic Stress 2:2470547018796102. https://doi.org/10.1177/2470547018796102
Abdallah CG, Averill LA, Gueorguieva R et al (2020) Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. Neuropsychopharmacology 45:990–997. https://doi.org/10.1038/s41386-020-0644-9
Abe R, Okada S, Nakayama R et al (2019) Social defeat stress causes selective attenuation of neuronal activity in the ventromedial PFC. Sci Rep 9:9447. https://doi.org/10.1038/s41598-019-45833-5
Ago Y, Tanabe W, Higuchi M et al (2019) (R)-Ketamine induces a greater increase in prefrontal 5-HT release than (S)-ketamine and ketamine metabolites via an AMPAR-independent mechanism. Int J Neuropsychopharmacol 22:665–674. https://doi.org/10.1093/ijnp/pyz041
Aguilar-Valles A, De Gregorio D, Matta-Camacho E et al (2021) Antidepressant actions of ketamine engage cell-specific translation via eIF4E. Nature 590:315–319. https://doi.org/10.1038/s41586-020-03047-0
Akinfiresoye L, Tizabi Y (2013) Antidepressant effects of AMPA and ketamine combination: role of HIPPampal BDNF, synapsin, and mTOR. Psychopharmacology 230:291–298. https://doi.org/10.1007/s00213-013-3153-2
Aleksandrova LR, Phillips AG, Wang YT (2017) Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDAR antagonism. J Psychiatry Neurosci 42:222–229. https://doi.org/10.1503/jpn.160175
Aleksandrova LR, Aleksandrova LR, Wang YT et al (2020) Ketamine and its metabolite, (2R,6R)-HNK, restore HIPPampal LTP and long-term spatial memory in the Wistar-Kyoto rat model of depression. Mol Brain 13:92. https://doi.org/10.1186/s13041-020-00627-z
Amat J, Dolzani SD, Tilden S et al (2016) Previous ketamine produces an enduring blockade of neurochemical and behavioral effects of uncontrollable stress. J Neurosci 36:153–161. https://doi.org/10.1523/JNEUROSCI.3114-15.2016
Anderzhanova E, Hafner K, Genewsky AJ et al (2020) The stress susceptibility factor FKBP51 controls S-Ketamine-evoked release of mBDNF in the PFC of mice. Neurobiol Stress 13:100239. https://doi.org/10.1016/j.ynstr.2020.100239
Araki R, Ago Y, Hasebe S et al (2014) Involvement of prefrontal AMPARs in encounter stimulation-induced hyperactivity in isolation-reared mice. Int J Neuropsychopharmacol 17:883–893. https://doi.org/10.1017/S1461145713001582
Ardalan M, Wegener G, Rafati AH, Nyengaard JR (2017) S-ketamine rapidly reverses synaptic and vascular deficits of HIPPampus in genetic animal model of depression. Int J Neuropsychopharmacol 20:247–256. https://doi.org/10.1093/ijnp/pyw098
Asim M, Hao B, Yang YH et al (2020) Ketamine alleviates fear generalization through GluN2B-BDNF signaling in mice. Neurosci Bull 36:153–164. https://doi.org/10.1007/s12264-019-00422-4
Autry AE, Adachi M, Nosyreva E et al (2011) NMDAR blockade at rest triggers rapid behavioural antidepressant responses. Nature 475:91–96. https://doi.org/10.1038/nature10130
Bagot RC, Cates HM, Purushothaman I et al (2017) Ketamine and imipramine reverse transcriptional signatures of susceptibility and induce resilience-specific gene expression profiles. Biol Psychiatry 81:285–295. https://doi.org/10.1016/j.biopsych.2016.06.012
Bambico FR, Li Z, Creed M et al (2020) A key role for prefrontocortical small conductance calcium-activated potassium channels in stress adaptation and rapid antidepressant response. Cereb Cortex 30:1559–1572. https://doi.org/10.1093/cercor/bhz187
Banasr M, Chowdhury GMI, Terwilliger R et al (2010) Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol Psychiatry 15:501–511. https://doi.org/10.1038/mp.2008.106
Barko K, Paden W, Cahill KM et al (2019) Sex-Specific effects of stress on mood-related gene expression. Mol Neuropsychiatry 5:162–176. https://doi.org/10.1159/000499105
Belleau EL, Treadway MT, Pizzagalli DA (2019) The impact of stress and major depressive disorder on HIPPampal and medial PFC morphology. Biol Psychiatry 85:443–453. https://doi.org/10.1016/j.biopsych.2018.09.031
Berman RM, Cappiello A, Anand A et al (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351–354. https://doi.org/10.1016/S0006-3223(99)00230-9
Beurel E, Song L, Jope RS (2011) Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol Psychiatry 16:1068–1070. https://doi.org/10.1038/mp.2011.47
Blum K, Pappas T, Clifton J et al (2019) Rapid anti-depressant relief by ketamine: exploring a complex mechanism of action. Curr Psychopharmacol 08:99–112. https://doi.org/10.2174/2211556008666190827150018
Bohacek J, Mansuy IM (2015) Molecular insights into transgenerational non-genetic inheritance of acquired behaviours. Nat Rev Genet 16:641–652. https://doi.org/10.1038/nrg3964
Bonhomme V, Vanhaudenhuyse A, Demertzi A et al (2016) Resting-state network-specific breakdown of functional connectivity during ketamine alteration of consciousness in volunteers. Anesthesiology 125:873–888. https://doi.org/10.1097/ALN.0000000000001275
Borsoi M, Nunes LED, Barbosa AR et al (2021) Intermittent repeated stress but not ketamine changes mice response to antidepressants. Neurosci Lett 741:135452. https://doi.org/10.1016/j.neulet.2020.135452
Bowman MA, Vitela M, Clarke KM et al (2020) Serotonin transporter and plasma membrane monoamine transporter are necessary for the antidepressant-like effects of ketamine in mice. Int J Mol Sci 21:7581. https://doi.org/10.3390/ijms21207581
Brachman RA, McGowan JC, Perusini JN et al (2016) Ketamine as a prophylactic against stress-induced depressive-like behavior. Biol Psychiatry 79:776–786. https://doi.org/10.1016/j.biopsych.2015.04.022
Browne CA, Lucki I (2013) Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Front Pharmacol 4:161. https://doi.org/10.3389/fphar.2013.00161
Burgdorf J, Zhang XL, Weiss C et al (2015) The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial PFC and HIPPampus. Neuroscience 308:202–211. https://doi.org/10.1016/j.neuroscience.2015.09.004
Can A, Zanos P, Moaddel R et al (2016) Effects of ketamine and ketamine metabolites on evoked striatal dopamine release, dopamine receptors, and monoamine transporters. J Pharmacol Exp Ther 359:159–170. https://doi.org/10.1124/jpet.116.235838
Can YS, Arnrich B, Ersoy C (2019) Stress detection in daily life scenarios using smart phones and wearable sensors: a survey. J Biomed Inform 92:103139. https://doi.org/10.1016/j.jbi.2019.103139
Carneiro D, Novais P, Augusto JC, Payne N (2019) New methods for stress assessment and monitoring at the workplace. IEEE Trans Affect Comput 10:37–254. https://doi.org/10.1109/TAFFC.2017.2699633
Chaki S (2017) Beyond ketamine: new approaches to the development of safer antidepressants. Curr Neuropharmacol 15:963–976. https://doi.org/10.2174/1570159x15666170221101054
Chaki S, Fukumoto K (2019) Role of serotonergic system in the antidepressant actions of mglu 2/3 receptor antagonists: similarity to ketamine. Int J Mol Sci 20:1270. https://doi.org/10.3390/ijms20061270
Chandran A, Iyo AH, Jernigan CS et al (2013) Reduced phosphorylation of the mTOR signaling pathway components in the amygdala of rats exposed to chronic stress. Prog Neuro-Psychopharmacol Biol Psychiatry 40:240–245. https://doi.org/10.1016/j.pnpbp.2012.08.001
Chang L, Zhang K, Pu Y et al (2019) Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-Ketamine, (R)-Ketamine, and (S)-Ketamine. Pharmacol Biochem Behav 181:53–59. https://doi.org/10.1016/j.pbb.2019.04.008
Chang L, Zhang K, Pu Y et al (2020) Lack of dopamine D1 receptors in the antidepressant actions of (R)-Ketamine in a chronic social defeat stress model. Eur Arch Psychiatry Clin Neurosci 270:271–275. https://doi.org/10.1007/s00406-019-01012-1
Chen BK, Mendez-David I, Luna VM et al (2020) Prophylactic efficacy of 5-HT4R agonists against stress. Neuropsychopharmacology 45:542–552. https://doi.org/10.1038/s41386-019-0540-3
Chiechio S, Canonico PL, Grilli M (2018) L-acetylcarnitine: a mechanistically distinctive and potentially rapid-acting antidepressant drug. Int J Mol Sci 19:11. https://doi.org/10.3390/ijms19010011
Chin CL, Upadhyay J, Marek GJ et al (2011) Awake rat pharmacological magnetic resonance imaging as a translational pharmacodynamic biomarker: Metabotropic glutamate 2/3 agonist modulation of ketamine-induced blood oxygenation level dependence signals. J Pharmacol Exp Ther 336:709–715. https://doi.org/10.1124/jpet.110.173880
Chiu CT, Scheuing L, Liu G et al (2015) The mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute Ketamine in a mouse model of stress. Int J Neuropsychopharmacol 18:pyu102. https://doi.org/10.1093/ijnp/pyu102
Choi KH, Berman RY, Zhang M et al (2020) Effects of ketamine on rodent fear memory. Int J Mol Sci 21:7173. https://doi.org/10.3390/ijms21197173
Chou D, Peng HY, Lin T Bin et al (2018) (2R,6R)-hydroxynorKetamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray. Neuropharmacology 139:1–12. doi:https://doi.org/10.1016/j.neuropharm.2018.06.033
Colucci-D’amato L, Speranza L, Volpicelli F (2020) Neurotrophic factor bdnf, physiological functions and therapeutic potential in depression, neurodegeneration and brain cancer. Int J Mol Sci 21:7777. https://doi.org/10.3390/ijms21207777
Cornwell BR, Salvadore G, Furey M et al (2012) Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biol Psychiatry 72:555–561. https://doi.org/10.1016/j.biopsych.2012.03.029
Costi S, Van Dam NT, Murrough JW (2015) Current status of ketamine and related therapies for mood and anxiety disorders. Curr Behav Neurosci Reports 2:216–225. https://doi.org/10.1007/s40473-015-0052-3
Czéh B, Fuchs E, Wiborg O, Simon M (2016) Animal models of major depression and their clinical implications. Prog Neuro-Psychopharmacol Biol Psychiatry 64:293–310. https://doi.org/10.1016/j.pnpbp.2015.04.004
de Kloet ER, Joëls M, Holsboer F (2005) Stress and the brain: from adaptation to disease. Nat Rev Neurosci 6:463–475. https://doi.org/10.1038/nrn1683
Delorenzo C, Dellagioia N, Bloch M et al (2015) In vivo ketamine-induced changes in [11C]ABP688 binding to metabotropic glutamate receptor subtype 5. Biol Psychiatry 77:266–275. https://doi.org/10.1016/j.biopsych.2014.06.024
Deyama S, Duman RS (2020) Neurotrophic mechanisms underlying the rapid and sustained antidepressant actions of ketamine. Pharmacol Biochem Behav 188:172837. https://doi.org/10.1016/j.pbb.2019.172837
Deyama S, Bang E, Wohleb ES et al (2019) Role of neuronal VEGF signaling in the PFC in the rapid antidepressant effects of ketamine. Am J Psychiatry 176:388–400. https://doi.org/10.1176/appi.ajp.2018.17121368
Dhama K, Latheef SK, Dadar M et al (2019) Biomarkers in stress related diseases/disorders: diagnostic, prognostic, and therapeutic values. Front Mol Biosci 6:91. https://doi.org/10.3389/fmolb.2019.00091
Dinas PC, Koutedakis Y, Flouris AD (2011) Effects of exercise and physical activity on depression. Ir J Med Sci 180:319–325. https://doi.org/10.1007/s11845-010-0633-9
Dolzani SD, Baratta MV, Moss JM et al (2018) Inhibition of a descending prefrontal circuit prevents Ketamine-induced stress resilience in females. eNeuro 5:ENEURO.0025-18.2018. https://doi.org/10.1523/ENEURO.0025-18.2018
Donello JE, Banerjee P, Li YX et al (2018) Positive N-methyl-D-aspartate receptor modulation by rapastinel promotes rapid and sustained antidepressant-like effects. Int J Neuropsychopharmacol 22:247–259. https://doi.org/10.1093/ijnp/pyy101
Dong C, Zhang JC, Yao W et al (2017) Rapid and sustained antidepressant action of the mGlu2/3 receptor antagonist MGS0039 in the social defeat stress model: comparison with ketamine. Int J Neuropsychopharmacol 20:228–236. https://doi.org/10.1093/ijnp/pyw089
Duman RS, Shinohara R, Fogaça MV, Hare B (2019) Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function. Mol Psychiatry 24:1816–1832. https://doi.org/10.1038/s41380-019-0400-x
Duman RS, Deyama S, Fogaça MV (2021) Role of BDNF in the pathophysiology and treatment of depression: activity-dependent effects distinguish rapid-acting antidepressants. Eur J Neurosci 53:126–139. https://doi.org/10.1111/ejn.14630
Duncan WC, Sarasso S, Ferrarelli F et al (2013) Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol 16:301–311. https://doi.org/10.1017/S1461145712000545
Dwyer JM, Lepack AE, Duman RS (2013) mGluR2/3 blockade produces rapid and long-lasting reversal of anhedonia caused by chronic stress exposure. J Mol Psychiatry 1:15. https://doi.org/10.1186/2049-9256-1-15
Edward Roberts R, Curran HV, Friston KJ, Morgan CJA (2014) Abnormalities in white matter microstructure associated with chronic ketamine use. Neuropsychopharmacology 39:329–338. https://doi.org/10.1038/npp.2013.195
Elhussiny MEA, Carini G, Mingardi J et al (2021) Modulation by chronic stress and ketamine of ionotropic AMPA/NMDA and metabotropic glutamate receptors in the rat HIPPampus. Prog Neuro-Psychopharmacol Biol Psychiatry 104:110033. https://doi.org/10.1016/j.pnpbp.2020.110033
Elmer GI, Tapocik JD, Mayo CL et al (2020) Ketamine metabolite (2R,6R)-hydroxynorKetamine reverses behavioral despair produced by adolescent trauma. Pharmacol Biochem Behav 196:172973. https://doi.org/10.1016/j.pbb.2020.172973
Eskelund A, Li Y, Budac DP et al (2017) Drugs with antidepressant properties affect tryptophan metabolites differently in rodent models with depression-like behavior. J Neurochem 142:118–131. https://doi.org/10.1111/jnc.14043
Esterlis I, DellaGioia N, Pietrzak RH et al (2018a) Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression. Mol Psychiatry 23:824–832. https://doi.org/10.1038/mp.2017.58
Esterlis I, Holmes SE, Sharma P et al (2018b) Metabotropic glutamatergic receptor 5 and stress disorders: knowledge gained from receptor imaging studies. Biol Psychiatry 84:95–105. https://doi.org/10.1016/j.biopsych.2017.08.025
Faye C, Mcgowan JC, Denny CA, David DJ (2018) Neurobiological mechanisms of stress resilience and implications for the aged population. Curr Neuropharmacol 16(3):234–270. https://doi.org/10.2174/1570159X15666170818095105
Feder A, Parides MK, Murrough JW et al (2014) Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiat 71:681–688. https://doi.org/10.1001/jamapsychiatry.2014.62
Fischell J, Van Dyke AM, Kvarta MD et al (2015) Rapid antidepressant action and restoration of excitatory synaptic strength after chronic stress by negative modulators of alpha 5-containing GABA A receptors. Neuropsychopharmacology 40:2499–2509. https://doi.org/10.1038/npp.2015.112
Fitzgerald PJ, Yen JY, Watson BO (2019) Stress-sensitive antidepressant-like effects of Ketamine in the mouse forced swim test. PLoS One 14:e0215554. https://doi.org/10.1371/journal.pone.0215554
Fleming LM, Javitt DC, Carter CS et al (2019) A multicenter study of ketamine effects on functional connectivity: large scale network relationships, hubs and symptom mechanisms. Neuro Image Clin 22:101739. https://doi.org/10.1016/j.nicl.2019.101739
Fogaça MV, Fukumoto K, Franklin T et al (2019) N-Methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects. Neuropsychopharmacology 44:2230–2238. https://doi.org/10.1038/s41386-019-0501-x
Fukumoto K, Iijima M, Chaki S (2016) The Antidepressant effects of an mGlu2/3 receptor antagonist and ketamine require AMPAR stimulation in the mPFC and subsequent activation of the 5-HT neurons in the DRN. Neuropsychopharmacology 41:1046–1056. https://doi.org/10.1038/npp.2015.233
Fukumoto K, Iijima M, Funakoshi T, Chaki S (2018) Role of 5-HT 1A receptor stimulation in the medial PFC in the sustained antidepressant effects of ketamine. Int J Neuropsychopharmacol 21:371–381. https://doi.org/10.1093/ijnp/pyx116
Fukumoto K, Fogaca MV, Liu RJ et al (2019) Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2R,6R)-hydroxynorKetamine. PNAS 116:297–302. https://doi.org/10.1073/pnas.1814709116
Fuller JJL, Murray RC, Horner KA (2015) D-amphetamine withdrawal-induced decreases in brain-derived neurotrophic factor in sprague-dawley rats are reversed by treatment with Ketamine. Neuropharmacology 97:7–17. https://doi.org/10.1016/j.neuropharm.2015.04.023
Gass N, Becker R, Reinwald J et al (2019) Differences between ketamine short-term and long-term effects on brain circuitry in depression. Transl Psychiatry 9:172. https://doi.org/10.1038/s41398-019-0506-6
Gass N, Becker R, Reinwald J et al (2020) The influence of ketamine repeated treatment on brain topology does not suggest an antidepressant efficacy. Transl Psychiatry 10:56. https://doi.org/10.1038/s41398-020-0727-8
Gassen NC, Hartmann J, Zschocke J et al (2014) Association of FKBP51 with priming of autophagy pathways and mediation of antidepressant treatment response: evidence in cells, mice, and humans. PLoS Med 11:e1001755. https://doi.org/10.1371/journal.pmed.1001755
Gerhard DM, Pothula S, Liu RJ et al (2020) GABA interneurons are the cellular trigger for ketamine rapid antidepressant actions. J Clin Invest 130:1336–1349. https://doi.org/10.1172/JCI130808
Getachew B, Aubee JI, Schottenfeld RS et al (2018) Ketamine interactions with gut-microbiota in rats: relevance to its antidepressant and anti-inflammatory properties. BMC Microbiol 18:222. https://doi.org/10.1186/s12866-018-1373-7
Ghosal S, Hare BD, Duman RS (2017) PFC GABAergic deficits and circuit dysfunction in the pathophysiology and treatment of chronic stress and depression. Curr Opin Behav Sci 14:1–8. https://doi.org/10.1016/j.cobeha.2016.09.012
Ghosal S, Duman CH, Liu RJ et al (2020) Ketamine rapidly reverses stress-induced impairments in GABAergic transmission in the PFC in male rodents. Neurobiol Dis 134:104669. https://doi.org/10.1016/j.nbd.2019.104669
Gigliucci V, O’Dowd G, Casey S et al (2013) Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism. Psychopharmacology 228:157–166. https://doi.org/10.1007/s00213-013-3024-x
Gilbert JR, Yarrington JS, Wills KE et al (2018) Glutamatergic signaling drives ketamine-mediated response in depression: evidence from dynamic causal modeling. Int J Neuropsychopharmacol 21:740–747. https://doi.org/10.1093/ijnp/pyy041
Girgenti MJ, Ghosal S, LoPresto D et al (2017) Ketamine accelerates fear extinction via mTORC1 signaling. Neurobiol Dis 100:1–8. https://doi.org/10.1016/j.nbd.2016.12.026
Gordillo-Salas M, Pilar-Cuéllar F, Auberson YP, Adell A (2018) Signaling pathways responsible for the rapid antidepressant-like effects of a GluN2A-preferring NMDAR antagonist. Transl Psychiatry 8:84. https://doi.org/10.1038/s41398-018-0131-9
Grieco SF, Cheng Y, Eldar-Finkelman H et al (2017) Up-regulation of insulin-like growth factor 2 by ketamine requires glycogen synthase kinase-3 inhibition. Prog Neuro-Psychopharmacol Biol Psychiatry 72:49–54. https://doi.org/10.1016/j.pnpbp.2016.08.008
Grimm O, Gass N, Weber-Fahr W et al (2015) Acute ketamine challenge increases resting state prefrontal-HIPPampal connectivity in both humans and rats. Psychopharmacology 232:4231–4241. https://doi.org/10.1007/s00213-015-4022-y
Grossert A, Mehrjardi NZ, Bailey SJ et al (2019) Ketamine increases proliferation of human iPSC-derived neuronal progenitor cells via insulin-like growth factor 2 and independent of the NMDAR. Cell 8:1139. https://doi.org/10.3390/cells8101139
Harraz MM, Snyder SH (2017) Antidepressant actions of ketamine mediated by the mechanistic target of rapamycin, nitric oxide, and rheb. Neurotherapeutics 14:728–733. https://doi.org/10.1007/s13311-017-0540-0
Hashimoto K (2019) Rapid-acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective. Psychiatry Clin Neurosci 73:613–627. https://doi.org/10.1111/pcn.12902
Hashimoto K (2020) Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine. Biochem Pharmacol 177:113935. https://doi.org/10.1016/j.bcp.2020.113935
Henderson TA (2016) Practical application of the neuroregenerative properties of ketamine: real world treatment experience. Neural Regen Res 11:195–200. https://doi.org/10.4103/1673-5374.177708
Herzog DP, Perumal N, Manicam C et al (2020) Title Longitudinal cerebrospinal fluid proteome profiling of acute and sustained antidepressant-like effects of (2R,6R)-hydroxynorKetamine (HNK) reveals involvement of glucocorticoid receptor signaling Corresponding author. bioRxiv 2020.09.03.280834. doi:https://doi.org/10.1101/2020.09.03.280834
Highland JN, Zanos P, Georgiou P, Gould TD (2019) Group II metabotropic glutamate receptor blockade promotes stress resilience in mice. Neuropsychopharmacology 44:1788–1796. https://doi.org/10.1038/s41386-019-0380-1
Hillhouse TM, Rice R, Porter JH (2019) What role does the (2R,6R)-hydronorKetamine metabolite play in the antidepressant-like and abuse-related effects of (R)-Ketamine? Br J Pharmacol 176:3886–3888. https://doi.org/10.1111/bph.14785
Ho MF, Zhang C, Zhang L et al (2019) Ketamine and active ketamine metabolites regulate STAT3 and the Type i interferon pathway in human microglia: molecular mechanisms linked to the antidepressant effects of ketamine. Front Pharmacol 10:1302. https://doi.org/10.3389/fphar.2019.01302
Hoepner CT, McIntyre RS, Papakostas GI (2021) Impact of supplementation and nutritional interventions on pathogenic processes of mood disorders: a review of the evidence. Nutrients 13:767. https://doi.org/10.3390/nu13030767
Holubova K, Kleteckova L, Skurlova M et al (2016) Rapamycin blocks the antidepressant effect of ketamine in task-dependent manner. Psychopharmacology 233:2077–2097. https://doi.org/10.1007/s00213-016-4256-3
Iadarola ND, Niciu MJ, Richards EM et al (2015) Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. Ther Adv Chronic Dis 6:97–114. https://doi.org/10.1177/2040622315579059
Jawaid A, Roszkowski M, Mansuy IM (2018) Transgenerational epigenetics of traumatic stress. Prog Mol Biol Transl Sci 158:273–298. https://doi.org/10.1016/bs.pmbts.2018.03.003
Jett JD, Boley AM, Girotti M et al (2015) Antidepressant-like cognitive and behavioral effects of acute ketamine administration associated with plasticity in the ventral HIPPampus to medial PFC pathway. Psychopharmacology 232:3123–3133. https://doi.org/10.1007/s00213-015-3957-3
Jiang Y, Wang Y, Sun X et al (2017) Short- and long-term antidepressant effects of ketamine in a rat chronic unpredictable stress model. Brain Behav 7:e00749. https://doi.org/10.1002/brb3.749
Jiang C, Lin WJ, Labonté B et al (2019) VGF and its C-terminal peptide TLQP-62 in ventromedial PFC regulate depression-related behaviors and the response to Ketamine. Neuropsychopharmacology 44:971–981. https://doi.org/10.1038/s41386-018-0277-4
Jie ZW, Hua WH, Dong LY et al (2018) Downregulation of Egr-1 expression level via GluN2B underlies the antidepressant effects of ketamine in a chronic unpredictable stress animal model of depression. Neuroscience 372:38–45. https://doi.org/10.1016/j.neuroscience.2017.12.045
Johnston JN, Thacker JS, Desjardins C et al (2020) Ketamine rescues HIPPampal reelin expression and synaptic markers in the repeated-corticosterone chronic stress paradigm. Front Pharmacol 11:559627. https://doi.org/10.3389/fphar.2020.559627
Kalmoe MC, Janski AM, Zorumski CF et al (2020) Ketamine and nitrous oxide: the evolution of NMDAR antagonists as antidepressant agents. J Neurol Sci 412:116778. https://doi.org/10.1016/j.jns.2020.116778
Kandola A, Ashdown-Franks G, Hendrikse J et al (2019) Physical activity and depression: towards understanding the antidepressant mechanisms of physical activity. Neurosci Biobehav Rev 107:525–539. https://doi.org/10.1016/j.neubiorev.2019.09.040
Kato T, Fogaça MV, Deyama S et al (2018) BDNF release and signaling are required for the antidepressant actions of GLYX-13. Mol Psychiatry 23:2007–2017. https://doi.org/10.1038/mp.2017.220
Khalili-Mahani N, Martini CH, Olofsen E et al (2015a) Effect of subanaesthetic ketamine on plasma and saliva cortisol secretion. Br J Anaesth 115:68–75. https://doi.org/10.1093/bja/aev135
Khalili-Mahani N, Niesters M, van Osch MJ et al (2015b) Ketamine interactions with biomarkers of stress: a randomized placebo-controlled repeated measures resting-state fMRI and PCASL pilot study in healthy men. NeuroImage 108:396–409. https://doi.org/10.1016/j.neuroimage.2014.12.050
Khan AR, Geiger L, Wiborg O, Czéh B (2020a) Stress-induced morphological, cellular and molecular changes in the brain-lessons learned from the chronic mild stress model of depression. Cell 9:1026. https://doi.org/10.3390/cells9041026
Kim CS, Johnston D (2020) Antidepressant effects of (S)-ketamine through a reduction of hyperpolarization-activated current Ih. iScience 23:101239. https://doi.org/10.1016/j.isci.2020.101239
Kiraly DD, Horn SR, Van Dam NT et al (2017) Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome. Transl Psychiatry 7:e1065. https://doi.org/10.1038/tp.2017.31
Klein ME, Chandra J, Sheriff S, Malinow R (2020) Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents. Proc Natl Acad Sci U S A 117:2656–2662. https://doi.org/10.1073/pnas.1916570117
Kokkinou M, Ashok AH, Howes OD (2018) The effects of Ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders. Mol Psychiatry 23:59–69. https://doi.org/10.1038/mp.2017.190
Kotoula V, Stringaris A, Mackes N et al (2020) Ketamine modulates the neural correlates of reward processing in unmedicated patients in remission from depression medRxiv 2020.12.07.20230151. doi:https://doi.org/10.1101/2020.12.07.20230151
Krystal JH, Abdallah CG, Averill LA et al (2017) Synaptic loss and the pathophysiology of PTSD: implications for ketamine as a prototype novel therapeutic. Curr Psychiatry Rep 19:74. https://doi.org/10.1007/s11920-017-0829-z
Krzystyniak A, Baczynska E, Magnowska M et al (2019) Prophylactic ketamine treatment promotes resilience to chronic stress and accelerates recovery: correlation with changes in synaptic plasticity in the CA3 subregion of the HIPPampus. Int J Mol Sci 20:1726. https://doi.org/10.3390/ijms20071726
Kuhlmann L, Foster BL, Liley DTJ (2013) Modulation of functional EEG networks by the NMDA antagonist nitrous oxide. PLoS One 8:e56434. https://doi.org/10.1371/journal.pone.0056434
Lally N, Nugent AC, Luckenbaugh DA et al (2015) Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. J Psychopharmacol 29:596–607. https://doi.org/10.1177/0269881114568041
Lei ZX, Sullivan JA, Moskal JR, Stanton PK (2008) A NMDAR glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in HIPPampus. Neuropharmacology 55:1238–1250. https://doi.org/10.1016/j.neuropharm.2008.08.018
Li N, Lee B, Liu RJ et al (2010) mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329:959–964. https://doi.org/10.1126/science.1190287
Li N, Liu RJ, Dwyer JM et al (2011) Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 69:754–761. https://doi.org/10.1016/j.biopsych.2010.12.015
Li JZ, Bunney BG, Meng F et al (2013) Circadian patterns of gene expression in the human brain and disruption in major depressive disorder. Proc Natl Acad Sci U S A 110:9950–9955. https://doi.org/10.1073/pnas.1305814110
Liao Y, Tang J, Ma M et al (2010) Frontal white matter abnormalities following chronic ketamine use: a diffusion tensor imaging study. Brain 133:2115–2122. https://doi.org/10.1093/brain/awq131
Liu RJ, Fuchikami M, Dwyer JM et al (2013) GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Neuropsychopharmacology 38:2268–2277. https://doi.org/10.1038/npp.2013.128
Liu WX, Wang J, Xie ZM et al (2016) Regulation of glutamate transporter 1 via BDNF-TrkB signaling plays a role in the anti-apoptotic and antidepressant effects of Ketamine in chronic unpredictable stress model of depression. Psychopharmacology 233:405–415. https://doi.org/10.1007/s00213-015-4128-2
Liu RJ, Duman C, Kato T et al (2017) GLYX-13 produces rapid antidepressant responses with key synaptic and behavioral effects distinct from ketamine. Neuropsychopharmacology 42:1231–1242. https://doi.org/10.1038/npp.2016.202
Lumey LH, Stein AD, Susser E (2011) Prenatal famine and adult health. Annu Rev Public Health 32:237–262. https://doi.org/10.1146/annurev-publhealth-031210-101230
Lumsden EW, Troppoli TA, Myers SJ et al (2019) Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorKetamine do not block NMDAR function. PNAS 116:5160–5169. https://doi.org/10.1073/pnas.1816071116
Luppino FS, De Wit LM, Bouvy PF et al (2010) Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 67:220–229. https://doi.org/10.1001/archgenpsychiatry.2010.2
Ly C, Greb AC, Cameron LP et al (2018) Psychedelics promote structural and functional neural plasticity. Cell Rep 23:3170–3182. https://doi.org/10.1016/j.celrep.2018.05.022
Ma Z, Zang T, Birnbaum SG et al (2017) TrkB dependent adult HIPPampal progenitor differentiation mediates sustained ketamine antidepressant response. Nat Commun 8:1668. https://doi.org/10.1038/s41467-017-01709-8
Maciel AL, Abelaira HM, de Moura AB et al (2018) Acute treatment with ketamine and chronic treatment with minocycline exert antidepressant-like effects and antioxidant properties in rats subjected different stressful events. Brain Res Bull 137:204–216. https://doi.org/10.1016/j.brainresbull.2017.12.005
Maltbie EA, Kaundinya GS, Howell LL (2017) Ketamine and pharmacological imaging: use of functional magnetic resonance imaging to evaluate mechanisms of action. Behav Pharmacol 28:610–622. https://doi.org/10.1097/FBP.0000000000000354
Martone G (2018) Enhancement of recovery from mental illness with l-methylfolate supplementation. Perspect Psychiatr Care 54:331–334. https://doi.org/10.1111/ppc.12227
Marx W, Moseley G, Berk M, Jacka F (2017) Nutritional psychiatry: the present state of the evidence. Proc Nutr Soc 76:427–436. https://doi.org/10.1017/S0029665117002026
Mastrodonato A, Martinez R, Pavlova IP et al (2018) Ventral CA3 activation mediates prophylactic ketamine efficacy against stress-induced depressive-like behavior. Biol Psychiatry 84:846–856. https://doi.org/10.1016/j.biopsych.2018.02.011
McEwen BS (2015) Biomarkers for assessing population and individual health and disease related to stress and adaptation. Metabolism 64:S2–S10. https://doi.org/10.1016/j.metabol.2014.10.029
McEwen BS (2016) In pursuit of resilience: stress, epigenetics, and brain plasticity. Ann N Y Acad Sci 1373:56–64. https://doi.org/10.1111/nyas.13020
McEwen BS, Akil H (2020) Revisiting the stress concept: implications for affective disorders. J Neurosci 40:12–21. https://doi.org/10.1523/JNEUROSCI.0733-19.2019
McEwen BS, Bowles NP, Gray JD et al (2015) Mechanisms of stress in the brain. Nat Neurosci 18:1353–1363. https://doi.org/10.1038/nn.4086
McGirr A, Ledue J, Chan AW et al (2017) Cortical functional hyperconnectivity in a mouse model of depression and selective network effects of ketamine. Brain 140:2210–2225. https://doi.org/10.1093/brain/awx142
McGowan JC, Lagamma CT, Lim SC et al (2017) Prophylactic ketamine attenuates learned fear. Neuropsychopharmacology 42:1577–1589. https://doi.org/10.1038/npp.2017.19
McGowan JC, Hill C, Mastrodonato A et al (2018) Prophylactic ketamine alters nucleotide and neurotransmitter metabolism in brain and plasma following stress. Neuropsychopharmacology 43:1813–1821. https://doi.org/10.1038/s41386-018-0043-7
McKendrick G, Garrett H, Jones HE et al (2020) Ketamine blocks morphine-induced conditioned place preference and anxiety-like behaviors in mice. Front Behav Neurosci 14:75. https://doi.org/10.3389/fnbeh.2020.00075
Milak MS, Proper CJ, Mulhern ST et al (2016) A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder. Mol Psychiatry 21:320–327. https://doi.org/10.1038/mp.2015.83
Milak MS, Rashid R, Dong Z et al (2020) Assessment of relationship of ketamine dose with magnetic resonance spectroscopy of Glx and GABA responses in adults with major depression: a randomized clinical trial. JAMA Netw Open 3:e2013211. https://doi.org/10.1001/jamanetworkopen.2020.13211
Milaneschi Y, Simmons WK, van Rossum EFC, Penninx BW (2019) Depression and obesity: evidence of shared biological mechanisms. Mol Psychiatry 24:18–33. https://doi.org/10.1038/s41380-018-0017-5
Miller AH, Maletic V, Raison CL (2009) Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65:732–741. https://doi.org/10.1016/j.biopsych.2008.11.029
Moaddel R, Shardell M, Khadeer M et al (2018) Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects. Psychopharmacology 235:3017–3030. https://doi.org/10.1007/s00213-018-4992-7
Moda-Sava RN, Murdock MH, Parekh PK et al (2019) Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science (80-) 364:eaat 8078. https://doi.org/10.1126/science.aat8078
Monje FJ, Cabatic M, Divisch I et al (2011) Constant darkness induces IL-6-dependent depression-like behavior through the NF-κB signaling pathway. J Neurosci 31:9075–9083. https://doi.org/10.1523/JNEUROSCI.1537-11.2011
Morgan CJA, Dodds CM, Furby H et al (2014) Long-term heavy ketamine use is associated with spatial memory impairment and altered HIPPampal activation. Front Psych 5:149. https://doi.org/10.3389/fpsyt.2014.00149
Moskal JR, Burch R, Burgdorf JS et al (2014) GLYX-13, an NMDAR glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDAR antagonists. Expert Opin Investig Drugs 23:243–254. https://doi.org/10.1517/13543784.2014.852536
Murrough JW, Iosifescu DV, Chang LC et al (2013) Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 170:1134–1142. https://doi.org/10.1176/appi.ajp.2013.13030392
Nagashima K, Zorumski CF, Izumi Y (2005) Nitrous oxide (laughing gas) facilitates excitability in rat HIPPampal slices through γ-aminobutyric acid A receptor-mediated disinhibition. Anesthesiology 102:230–234. https://doi.org/10.1097/00000542-200501000-00034
Nagele P, Duma A, Kopec M et al (2015) Nitrous oxide for treatment-resistant major depression: a proof-of-concept trial. Biol Psychiatry 78:10–18. https://doi.org/10.1016/j.biopsych.2014.11.016
Nasca C, Bigio B, Zelli D et al (2017) Role of the astroglial glutamate exchanger xCT in ventral HIPPampus in resilience to stress. Neuron 96:402–413.e5. https://doi.org/10.1016/j.neuron.2017.09.020
Neis VB, Bettio LEB, Moretti M et al (2016) Acute agmatine administration, similar to Ketamine, reverses depressive-like behavior induced by chronic unpredictable stress in mice. Pharmacol Biochem Behav 150–151:108–114. https://doi.org/10.1016/j.pbb.2016.10.004
Ng LHL, Huang Y, Han L et al (2018) Ketamine and selective activation of parvalbumin interneurons inhibit stress-induced dendritic spine elimination. Transl Psychiatry 8:272. https://doi.org/10.1038/s41398-018-0321-5
Nishitani N, Nagayasu K, Asaoka N et al (2014) Raphe AMPARs and nicotinic acetylcholine receptors mediate Ketamine-induced serotonin release in the rat PFC. Int J Neuropsychopharmacol 17:1321–1326. https://doi.org/10.1017/S1461145714000649
Nowak W, Grendas LN, Sanmarco LM et al (2019) Pro-inflammatory monocyte profile in patients with major depressive disorder and suicide behaviour and how ketamine induces anti-inflammatory M2 macrophages by NMDAR and mTOR. EBioMedicine 50:290–305. https://doi.org/10.1016/j.ebiom.2019.10.063
Nugent AC, Ballard ED, Gould TD et al (2019) Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects. Mol Psychiatry 24:1040–1052. https://doi.org/10.1038/s41380-018-0028-2
Okine T, Shepard R, Lemanski E, Coutellier L (2020) Sex differences in the sustained effects of ketamine on resilience to chronic stress. Front Behav Neurosci 14:581360. https://doi.org/10.3389/fnbeh.2020.581360
Orozco-Solis R, Montellier E, Aguilar-Arnal L et al (2017) A circadian genomic signature common to ketamine and sleep deprivation in the anterior cingulate cortex. Biol Psychiatry 82:351–360. https://doi.org/10.1016/j.biopsych.2017.02.1176
Park M, Newman LE, Gold PW et al (2017) Change in cytokine levels is not associated with rapid antidepressant response to Ketamine in treatment-resistant depression. J Psychiatr Res 84:113–118. https://doi.org/10.1016/j.jpsychires.2016.09.025
Patel D, Kas MJ, Chattarji S, Buwalda B (2019) Rodent models of social stress and neuronal plasticity: relevance to depressive-like disorders. Behav Brain Res 369:111900. https://doi.org/10.1016/j.bbr.2019.111900
Patton MS, Lodge DJ, Morilak DA, Girotti M (2017) Ketamine corrects stress-induced cognitive dysfunction through JAK2/STAT3 signaling in the orbitofrontal cortex. Neuropsychopharmacology 42:1220–1230. https://doi.org/10.1038/npp.2016.236
Pereira VS, Hiroaki-Sato VA (2018) A brief history of antidepressant drug development: from tricyclics to beyond ketamine. Acta Neuropsychiatr 30:307–322. https://doi.org/10.1017/neu.2017.39
Phillips C (2017) Brain-derived neurotrophic factor, depression, and physical activity: making the neuroplastic connection. Neural Plast 2017:7260130. https://doi.org/10.1155/2017/7260130
Phoumthipphavong V, Barthas F, Hassett S, Kwan AC (2016) Longitudinal effects of ketamine on dendritic architecture in vivo in the mouse medial frontal cortex. eNeuro 3:ENEURO.0133-15. https://doi.org/10.1523/ENEURO.0133-15.2016
Planchez B, Surget A, Belzung C (2019) Animal models of major depression: drawbacks and challenges. J Neural Transm 126:1383–1408. https://doi.org/10.1007/s00702-019-02084-y
Polis AJ, Fitzgerald PJ, Hale PJ, Watson BO (2019) Rodent ketamine depression-related research: finding patterns in a literature of variability. Behav Brain Res 376:112153. https://doi.org/10.1016/j.bbr.2019.112153
Pradhan B, Kluewer D’Amico J, Makani R, Parikh T (2016) Nonconventional interventions for chronic post-traumatic stress disorder: ketamine, repetitive trans-cranial magnetic stimulation (rTMS), and alternative approaches. J Trauma Dissociation 17:35–54. https://doi.org/10.1080/15299732.2015.1046101
Preskorn SH, Baker B, Kolluri S et al (2008) An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective n-methyl-d-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 28:631–637. https://doi.org/10.1097/JCP.0b013e31818a6cea
Preskorn S, Macaluso M, Mehra V et al (2015) Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatr Pract 21:140–149. https://doi.org/10.1097/01.pra.0000462606.17725.93
Qu Y, Yang C, Ren Q et al (2017) Comparison of (R)-ketamine and lanicemine on depression-like phenotype and abnormal composition of gut microbiota in a social defeat stress model. Sci Rep 7:15725. https://doi.org/10.1038/s41598-017-16060-7
Ramaker MJ, Dulawa SC (2017) Identifying fast-onset antidepressants using rodent models. Mol Psychiatry 22:656–665. https://doi.org/10.1038/mp.2017.36
Ramos-Lopez O, Milagro FI, Riezu-Boj JI, Martinez JA (2021) Epigenetic signatures underlying inflammation: an interplay of nutrition, physical activity, metabolic diseases, and environmental factors for personalized nutrition. Inflamm Res 70:29–49. https://doi.org/10.1007/s00011-020-01425-y
Reed JL, Nugent AC, Furey ML et al (2018) Ketamine normalizes brain activity during emotionally valenced attentional processing in depression. NeuroImage Clin 20:92–101. https://doi.org/10.1016/j.nicl.2018.07.006
Riggs LM, Aracava Y, Zanos P et al (2020) (2R,6R)-hydroxynorKetamine rapidly potentiates HIPPampal glutamatergic transmission through a synapse-specific presynaptic mechanism. Neuropsychopharmacology 45:426–436. https://doi.org/10.1038/s41386-019-0443-3
Rincón-Cortés M, Grace AA (2017) Sex-dependent effects of stress on immobility behavior and VTA dopamine neuron activity: modulation by ketamine. Int J Neuropsychopharmacol 20:823–832. https://doi.org/10.1093/ijnp/pyx048
Rincón-Cortés M, Grace AA (2020) Antidepressant effects of ketamine on depression-related phenotypes and dopamine dysfunction in rodent models of stress. Behav Brain Res 379:112367. https://doi.org/10.1016/j.bbr.2019.112367
Rotroff DM, Corum DG, Motsinger-Reif A et al (2016) Metabolomic signatures of drug response phenotypes for ketamine and esKetamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants. Transl Psychiatry 6:e894. https://doi.org/10.1038/tp.2016.145
Saland SK, Duclot F, Kabbaj M (2017) Integrative analysis of sex differences in the rapid antidepressant effects of ketamine in preclinical models for individualized clinical outcomes. Curr Opin Behav Sci 14:19–26. https://doi.org/10.1016/j.cobeha.2016.11.002
Sanacora G, Smith MA, Pathak S et al (2014) Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry 19:978–985. https://doi.org/10.1038/mp.2013.130
Sanacora G, Johnson MR, Khan A et al (2017) Adjunctive lanicemine (AZD6765) in patients with major depressive disorder and history of inadequate response to antidepressants: a randomized, placebo-controlled study. Neuropsychopharmacology 42:844–853. https://doi.org/10.1038/npp.2016.224
Sarris J (2019) Nutritional psychiatry: from concept to the clinic. Drugs 79:929–934. https://doi.org/10.1007/s40265-019-01134-9
Sattar Y, Wilson J, Khan AM et al (2018) A Review of the mechanism of antagonism of N-methyl-D-aspartate receptor by ketamine in treatment-resistant depression. Cureus 10:e2652. https://doi.org/10.7759/cureus.2652
Shin C, Kim YK (2020) Ketamine in major depressive disorder: mechanisms and future perspectives. Psychiatry Investig 17:181–192. https://doi.org/10.30773/pi.2019.0236
Shin S, Kwon O, Kang JI et al (2015) mGluR5 in the NAcis critical for promoting resilience to chronic stress. Nat Neurosci 18:1017–1024. https://doi.org/10.1038/nn.4028
Silberbauer LR, Spurny B, Handschuh P et al (2020) Effect of ketamine on limbic GABA and glutamate: a human in vivo multivoxel magnetic resonance spectroscopy study. Front Psych 11:549903. https://doi.org/10.3389/fpsyt.2020.549903
Singh JB, Fedgchin M, Daly EJ et al (2016) A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry 173:816–826. https://doi.org/10.1176/appi.ajp.2016.16010037
Sofia RD, Harakal JJ (1975) Evaluation of ketamine HCl for anti-depressant activity. Arch Int Pharmacodyn Ther 214:68–74
Sowa J, Kusek M, Bobula B et al (2019) Ketamine administration reverses corticosterone-induced alterations in excitatory and inhibitory transmission in the rat dorsal raphe nucleus. Neural Plast 2019:3219490. https://doi.org/10.1155/2019/3219490
Sun HL, Zhou ZQ, Zhang GF et al (2016) Role of HIPPampal p11 in the sustained antidepressant effect of ketamine in the chronic unpredictable mild stress model. Transl Psychiatry 6:e741. https://doi.org/10.1038/tp.2016.21
Sun Y, Wang D, Salvadore G et al (2017) The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman’s disease. Brain Behav Immun 66:156–164. https://doi.org/10.1016/j.bbi.2017.06.014
Suzuki K, Nosyreva E, Hunt KW et al (2017) Effects of a ketamine metabolite on synaptic NMDAR function. Nature 546:E1–E3. https://doi.org/10.1038/nature22084
Talbot JN, Geffert LM, Jorvig JE et al (2016) Rapid and sustained antidepressant properties of an NMDA antagonist/monoamine reuptake inhibitor identified via transporter-based virtual screening. Pharmacol Biochem Behav 150–151:22–30. https://doi.org/10.1016/j.pbb.2016.08.007
Tan BL, Norhaizan ME (2019) Effect of high-fat diets on oxidative stress, cellular inflammatory response and cognitive function. Nutrients 11:2579. https://doi.org/10.3390/nu11112579
Tan S, Wang Y, Chen K et al (2017) Ketamine alleviates depressive-like behaviors via down-regulating inflammatory cytokines induced by chronic restraint stress in mice. Biol Pharm Bull 40:1260–1267. https://doi.org/10.1248/bpb.b17-00131
Tang J, Xue W, Xia B et al (2015) Involvement of normalized NMDAR and mTOR-related signaling in rapid antidepressant effects of yueju and ketamine on chronically stressed mice. Sci Rep 5:13573. https://doi.org/10.1038/srep13573
Tang YY, Askari P, Choi C (2020) Brief mindfulness training increased glutamate metabolism in the anterior cingulate cortex. Neuroreport 31:1142–1145. https://doi.org/10.1097/WNR.0000000000001527
Taylor JH, Landeros-Weisenberger A, Coughlin C et al (2018) Ketamine for social anxiety disorder: a randomized, placebo-controlled crossover trial. Neuropsychopharmacology 43:325–333. https://doi.org/10.1038/npp.2017.194
Ting EYC, Yang AC, Tsai SJ (2020) Role of interleukin-6 in depressive disorder. Int J Mol Sci 21:2194. https://doi.org/10.3390/ijms21062194
Tornese P, Sala N, Bonini D et al (2019) Chronic mild stress induces anhedonic behavior and changes in glutamate release, BDNF trafficking and dendrite morphology only in stress vulnerable rats. The rapid restorative action of ketamine. Neurobiol Stress 10:100160. https://doi.org/10.1016/j.ynstr.2019.100160
Torres-Berrío A, Issler O, Parise EM, Nestler EJ (2019) Unraveling the epigenetic landscape of depression: focus on early life stress. Dialogues Clin Neurosci 21:341–357. https://doi.org/10.31887/DCNS.2019.21.4/enestler
Trofimiuk E, Wielgat P, Braszko JJ, Car H (2019) Stress and ketamine, bimodal influence on cognitive functions. Behav Brain Res 360:354–364. https://doi.org/10.1016/j.bbr.2018.12.030
van der Kooij MA (2020) The impact of chronic stress on energy metabolism. Mol Cell Neurosci 107:103525. https://doi.org/10.1016/j.mcn.2020.103525
Voleti B, Navarria A, Liu RJ et al (2013) Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol Psychiatry 74:742–749. https://doi.org/10.1016/j.biopsych.2013.04.025
Wang J, Jing L, Toledo-Salas JC, Xu L (2015) Rapid-onset antidepressant efficacy of glutamatergic system modulators: the neural plasticity hypothesis of depression. Neurosci Bull 31:75–86. https://doi.org/10.1007/s12264-014-1484-6
Wang Q, Timberlake MA, Prall K, Dwivedi Y (2017) The recent progress in animal models of depression. Prog Neuro-Psychopharmacol Biol Psychiatry 77:99–109. https://doi.org/10.1016/j.pnpbp.2017.04.008
Weckmann K, Labermaier C, Asara JM et al (2014) Time-dependent metabolomic profiling of ketamine drug action reveals HIPPampal pathway alterations and biomarker candidates. Transl Psychiatry 4:e481. https://doi.org/10.1038/tp.2014.119
Wei Y, Chang L, Hashimoto K (2020a) A historical review of antidepressant effects of Ketamine and its enantiomers. Pharmacol Biochem Behav 190
Wei MD, Wang YH, Lu K et al (2020b) Ketamine reverses the impaired fear memory extinction and accompanied depressive-like behaviors in adolescent mice. Behav Brain Res 379:112342. https://doi.org/10.1016/j.bbr.2019.112342
Widman AJ, McMahon LL (2018) Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy. PNAS 115:E3007–E3016. https://doi.org/10.1073/pnas.1718883115
Williams NR, Heifets BD, Bentzley BS et al (2019) Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism. Mol Psychiatry 24:1779–1786. https://doi.org/10.1038/s41380-019-0503-4
Willner P (2005) Chronic mild stress (CMS) revisited: consistency and behavioural- neurobiological concordance in the effects of CMS. Neuropsychobiology 52:90–110. https://doi.org/10.1159/000087097
Willner P (2016) The chronic mild stress (CMS) model of depression: History, evaluation and usage. Neurobiol Stress 6:78–93. https://doi.org/10.1016/j.ynstr.2016.08.002
Willner P, Mitchell PJ (2002) The validity of animal models of predisposition to depression. Behav Pharmacol 13:169–188. https://doi.org/10.1097/00008877-200205000-00001
Witkin JM, Monn JA, Schoepp DD et al (2016) The rapidly acting antidepressant ketamine and the mGlu2/3 receptor antagonist LY341495 rapidly engage dopaminergic mood circuits. J Pharmacol Exp Ther 358:71–82. https://doi.org/10.1124/jpet.116.233627
Woelfer M, Li M, Colic L et al (2020) Ketamine-induced changes in plasma brain-derived neurotrophic factor (BDNF) levels are associated with the resting-state functional connectivity of the PFC. World J Biol Psychiatry 21:696–710. https://doi.org/10.1080/15622975.2019.1679391
Wright KN, Hagarty DP, Strong CE et al (2019) Sex-dependent ketamine addiction-like behavior profile following exposure to chronic mild stress. Chronic Stress 3:247054701983261. https://doi.org/10.1177/2470547019832613
Wu M, Minkowicz S, Dumrongprechachan V et al (2020) Ketamine restores escape behavior by re-engaging dopamine systems to drive cortical spinogenesis bioRxiv 2020.03.11.987818. doi:https://doi.org/10.1101/2020.03.11.987818
Xiong Z, Zhang K, Ishima T et al (2018) Comparison of rapid and long-lasting antidepressant effects of negative modulators of α5-containing GABAA receptors and (R)-ketamine in a chronic social defeat stress model. Pharmacol Biochem Behav 175:139–145. https://doi.org/10.1016/j.pbb.2018.10.005
Xu L, Nan J, Lan Y (2020) The nucleus accumbens: a common target in the comorbidity of depression and addiction. Front Neural Circuits 14:37. https://doi.org/10.3389/fncir.2020.00037
Yan W, Liu JF, Han Y et al (2018) Protein kinase Mζ in medial PFC mediates depressive-like behavior and antidepressant response. Mol Psychiatry 23:1878–1891. https://doi.org/10.1038/mp.2017.219
Yang C, Shirayama Y, Zhang JC et al (2015) R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry 5:e632. https://doi.org/10.1038/tp.2015.136
Yang B, Chun ZJ, Han M et al (2016) Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression. Psychopharmacology 233:3647–3657. https://doi.org/10.1007/s00213-016-4399-2
Yang C, Qu Y, Fujita Y et al (2017) Possible role of the gut microbiota-brain axis in the antidepressant effects of (R)-Ketamine in a social defeat stress model. Transl Psychiatry 7:1294. https://doi.org/10.1038/s41398-017-0031-4
Yang C, Kobayashi S, Nakao K et al (2018a) AMPAR activation–independent antidepressant actions of ketamine metabolite (S)-NorKetamine. Biol Psychiatry 84:591–600. https://doi.org/10.1016/j.biopsych.2018.05.007
Yang C, Ren Q, Qu Y et al (2018b) Mechanistic target of rapamycin–independent antidepressant effects of (R)-ketamine in a social defeat stress model. Biol Psychiatry 83:18–28. https://doi.org/10.1016/j.biopsych.2017.05.016
Yang Y, Ju W, Zhang H, Sun L (2018c) Effect of ketamine on LTP and NMDAR EPSC in HIPPampus of the chronic social defeat stress mice model of depression. Front Behav Neurosci 12:229. https://doi.org/10.3389/fnbeh.2018.00229
Yang C, Yang J, Luo A, Hashimoto K (2019) Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites. Transl Psychiatry 9:280. https://doi.org/10.1038/s41398-019-0624-1
Yao N, Skiteva O, Zhang X et al (2018) Ketamine and its metabolite (2R,6R)-hydroxynorKetamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit. Mol Psychiatry 23:2066–2077. https://doi.org/10.1038/mp.2017.239
Yoon G, Petrakis IL, Krystal JH (2019) Association of combined naltrexone and ketamine with depressive symptoms in a case series of patients with depression and alcohol use disorder. JAMA Psychiat 76:337–338. https://doi.org/10.1001/jamapsychiatry.2018.3990
Zanos P, Gould TD (2018) Intracellular signaling pathways involved in (S)- and (R)-ketamine antidepressant actions. Biol Psychiatry 83:2–4. https://doi.org/10.1016/j.biopsych.2017.10.026
Zanos P, Moaddel R, Morris PJ et al (2016) NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533:481–486. https://doi.org/10.1038/nature17998
Zanos P, Highland JN, Liu X et al (2019a) (R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorKetamine, while causing adverse effects at sub-anaesthetic doses. Br J Pharmacol 176:2573–2592. https://doi.org/10.1111/bph.14683
Zanos P, Highland JN, Stewart BW et al (2019b) (2R,6R)-hydroxynorKetamine exerts mGlu2 receptordependent antidepressant actions. PNAS 116:6441–6450. https://doi.org/10.1073/pnas.1819540116
Zarate CA, Mathews D, Ibrahim L et al (2013) A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol Psychiatry 74:257–264. https://doi.org/10.1016/j.biopsych.2012.10.019
Zhang LM, Zhou WW, Ji YJ et al (2015) Anxiolytic effects of ketamine in animal models of posttraumatic stress disorder. Psychopharmacology 232:663–672. https://doi.org/10.1007/s00213-014-3697-9
Zhang F, Luo J, Zhu X (2018a) Ketamine ameliorates depressive-like behaviors by tPA-mediated conversion of proBDNF to mBDNF in the HIPPampus of stressed rats. Psychiatry Res 269:646–651. https://doi.org/10.1016/j.psychres.2018.08.075
Zhang K, Fujita Y, Hashimoto K (2018b) Lack of metabolism in (R)-Ketamine antidepressant actions in a chronic social defeat stress model. Sci Rep 8:4007. https://doi.org/10.1038/s41598-018-22449-9
Zhang J, Qu Y, Chang L et al (2019) (R)-Ketamine rapidly ameliorates the decreased spine density in the medial PFC and HIPPampus of susceptible mice after chronic social defeat stress. Int J Neuropsychopharmacol 22:675–679. https://doi.org/10.1093/ijnp/pyz048
Zhang K, Yang C, Chang L et al (2020a) Essential role of microglial transforming growth factor-β1 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-β1. Transl Psychiatry 10:32. https://doi.org/10.1038/s41398-020-0733-x
Zhang W, Sun Q, Jia L, Li M (2020b) Ketamine exerts a protective role in a cell-based model of major depressive disorder via the inhibition of apoptosis and inflammation and activation of the Krebs cycle. Bosn J Basic Med Sci 20:44–55. https://doi.org/10.17305/bjbms.2019.4222
Zhou YL, Wu FC, Liu WJ et al (2020) Volumetric changes in subcortical structures following repeated ketamine treatment in patients with major depressive disorder: a longitudinal analysis. Transl Psychiatry 10:264. https://doi.org/10.1038/s41398-020-00945-9
Zhu X, Ye G, Wang Z et al (2017) Sub-anesthetic doses of ketamine exert antidepressant-like effects and upregulate the expression of glutamate transporters in the HIPPampus of rats. Neurosci Lett 639:132–137. https://doi.org/10.1016/j.neulet.2016.12.070
Zhuo C, Tian H, Li G et al (2019) Effects of Ketamine on circadian rhythm and synaptic homeostasis in patients with treatment-resistant depression: a protocol for mechanistic studies of its rapid and sustained antidepressant actions in humans. Brain Behav 9:e01423. https://doi.org/10.1002/brb3.1423
Zorumski CF, Nagele P, Mennerick S, Conway CR (2015) Treatment-resistant major depression: rationale for NMDARs as targets and nitrous oxide as therapy. Front Psych 6:172. https://doi.org/10.3389/fpsyt.2015.00172
Zucchi FCR, Yao Y, Metz GA (2012) The secret language of destiny: stress imprinting and transgenerational origins of disease. Front Genet 3:96. https://doi.org/10.3389/fgene.2012.00096
Suggested Reading
Christian KM, Miracle AD, Wellman CL, Nakazawa K (2011) Chronic stress-induced HIPPampal dendritic retraction requires CA3 NMDARs. Neuroscience 174:26–36. https://doi.org/10.1016/j.neuroscience.2010.11.033
Geng C, Qiao Y, Guo Y et al (2019) Integrated metabolomics and lipidomics profiling of HIPPampus reveal metabolite biomarkers in a rat model of chronic unpredictable mild stress-induced depression. Ann Transl Med 7:781–781. https://doi.org/10.21037/atm.2019.11.21
Iyo AH, Feyissa AM, Chandran A et al (2010) Chronic corticosterone administration down-regulates metabotropic glutamate receptor 5 protein expression in the rat HIPPampus. Neuroscience 169:1567–1574. https://doi.org/10.1016/j.neuroscience.2010.06.023
Khan AR, Kroenke CD, Wiborg O et al (2018) Differential microstructural alterations in rat cerebral cortex in a model of chronic mild stress depression. PLoS One 13:e0192329. https://doi.org/10.1371/journal.pone.0192329
Khan AR, Geiger L, Wiborg O, Czéh B (2020b) Stress-induced morphological, cellular and molecular changes in the brain-lessons learned from the chronic mild stress model of depression. Cell 9:1026. https://doi.org/10.3390/cells9041026
Li S, Wang C, Wang W et al (2008) Chronic mild stress impairs cognition in mice: from brain homeostasis to behavior. Life Sci 82:934–942. https://doi.org/10.1016/j.lfs.2008.02.010
Nasca C, Zelli D, Bigio B et al (2015) Stress dynamically regulates behavior and glutamatergic gene expression in HIPPampus by opening a window of epigenetic plasticity. Proc Natl Acad Sci U S A 112:14960–14965. https://doi.org/10.1073/pnas.1516016112
Park MJ, Seo BA, Lee B et al (2018) Stress-induced changes in social dominance are scaled by AMPA-type glutamate receptor phosphorylation in the medial PFC. Sci Rep 8:15008. https://doi.org/10.1038/s41598-018-33410-1
Qiao H, Li MX, Xu C et al (2016) Dendritic spines in depression: what we learned from animal models. Neural Plast 2016:8056370. https://doi.org/10.1155/2016/8056370
Rao C, Shi H, Zhou C et al (2016) Hypothalamic proteomic analysis reveals dysregulation of glutamate balance and energy metabolism in a mouse model of chronic mild stress-induced depression. Neurochem Res 41:2443–2456. https://doi.org/10.1007/s11064-016-1957-2
Tordera RM, Garcia-García AL, Elizalde N et al (2011) Chronic stress and impaired glutamate function elicit a depressive-like phenotype and common changes in gene expression in the mouse frontal cortex. Eur Neuropsychopharmacol 21:23–32. https://doi.org/10.1016/j.euroneuro.2010.06.016
Zyana S, Dominguez N, Chien-Liang A, Lin G (2016) Role of glutamate transporter EAAT2 in stress-induced depression. The Ohio State University
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Coutellier, L.D., Musazzi, L., Pavlovic, Z.M. (2022). Current Glutamatergic Treatments and Future Directions for Glutamate-Based Management of Chronic Stress and Stress-Related Disorders. In: Pavlovic, Z.M. (eds) Glutamate and Neuropsychiatric Disorders. Springer, Cham. https://doi.org/10.1007/978-3-030-87480-3_4
Download citation
DOI: https://doi.org/10.1007/978-3-030-87480-3_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-87479-7
Online ISBN: 978-3-030-87480-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)